We postulate trametinib as a novel effective targeted agent to treat RMS, similarly as in pediatric glioma [58, 59], when metronomically combined with MCL-1 inhibitors such as S63845; also in ARMS, a RMS subtype that has a high propensity for metastases and presents poor prognosis [6, 50], may be clinically relevant. The gene discussed is MCL1; the disease is glioma.